Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status
Abstract The serendipitous discovery that inhibiting type 5 phosphodiesterase (PDE5) using sildenafil, a potent PDE5 inhibitor (PDE5i) initially developed for cardioprotection, introduced the possibility of orally managing erectile dysfunction (ED) led to an increase in research data, which are curr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Basic and Clinical Andrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12610-024-00245-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571918577827840 |
|---|---|
| author | Andrea Sansone Eugenia Guida Susanna Dolci Valeria Frangione Amanda Asso Gilberto Bellia Emmanuele A. Jannini |
| author_facet | Andrea Sansone Eugenia Guida Susanna Dolci Valeria Frangione Amanda Asso Gilberto Bellia Emmanuele A. Jannini |
| author_sort | Andrea Sansone |
| collection | DOAJ |
| description | Abstract The serendipitous discovery that inhibiting type 5 phosphodiesterase (PDE5) using sildenafil, a potent PDE5 inhibitor (PDE5i) initially developed for cardioprotection, introduced the possibility of orally managing erectile dysfunction (ED) led to an increase in research data, which are currently considered groundbreaking for the new discipline of sexual medicine. Findings from a number of laboratories and clinics around the world unanimously demonstrated the following: (i) the major cause of ED is directly or indirectly related to cardiovascular disease (CVD); (ii) ED and CVDs share the same risk factors, which are related mainly to lifestyle choices; (iii) the first therapeutic approach to both ED and CVDs is to transform harmful lifestyles into virtuous lifestyles; and (iv) PDE5is in general, particularly sildenafil, are very safe, if not protective, for use in CVD patients. However, the use of PDE5is has faced several challenges. Many patients and some healthcare providers (HCPs) often share the misconception that using these drugs can increase the risk of CVD. Some patients might desire to fulfill the unmet need for privacy linked to the stigma of being treated for ED or might be enticed by the idea of buying drugs online, either because of shame or cheaper prices, without knowing the risks associated with counterfeit drugs. The aim of this narrative revision of the current literature is to demonstrate that (i) the orodispersible film of sildenafil is safe from a CV perspective; (ii) it is a discreet formulation that respects the need for privacy; and (iii) it is virtually the unique PDE5i formulation too expensive to produce outside the correct channels, making it impossible to be counterfeit. |
| format | Article |
| id | doaj-art-36e87ae5a647479685cbaa59b6e71379 |
| institution | Kabale University |
| issn | 2051-4190 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Basic and Clinical Andrology |
| spelling | doaj-art-36e87ae5a647479685cbaa59b6e713792025-02-02T12:12:38ZengBMCBasic and Clinical Andrology2051-41902025-01-0135111310.1186/s12610-024-00245-yFuture perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological statusAndrea Sansone0Eugenia Guida1Susanna Dolci2Valeria Frangione3Amanda Asso4Gilberto Bellia5Emmanuele A. Jannini6Chair of Endocrinology and Medical Sexology (ENDOSEX), Dept. of Systems Medicine, University of Rome Tor VergataChair of Anatomy, Dept. of Biomedicine and Prevention, University of Rome Tor VergataChair of Anatomy, Dept. of Biomedicine and Prevention, University of Rome Tor VergataIBSA Institut Biochimique SAIBSA Farmaceutici Italia S.r.lIBSA Farmaceutici Italia S.r.lChair of Endocrinology and Medical Sexology (ENDOSEX), Dept. of Systems Medicine, University of Rome Tor VergataAbstract The serendipitous discovery that inhibiting type 5 phosphodiesterase (PDE5) using sildenafil, a potent PDE5 inhibitor (PDE5i) initially developed for cardioprotection, introduced the possibility of orally managing erectile dysfunction (ED) led to an increase in research data, which are currently considered groundbreaking for the new discipline of sexual medicine. Findings from a number of laboratories and clinics around the world unanimously demonstrated the following: (i) the major cause of ED is directly or indirectly related to cardiovascular disease (CVD); (ii) ED and CVDs share the same risk factors, which are related mainly to lifestyle choices; (iii) the first therapeutic approach to both ED and CVDs is to transform harmful lifestyles into virtuous lifestyles; and (iv) PDE5is in general, particularly sildenafil, are very safe, if not protective, for use in CVD patients. However, the use of PDE5is has faced several challenges. Many patients and some healthcare providers (HCPs) often share the misconception that using these drugs can increase the risk of CVD. Some patients might desire to fulfill the unmet need for privacy linked to the stigma of being treated for ED or might be enticed by the idea of buying drugs online, either because of shame or cheaper prices, without knowing the risks associated with counterfeit drugs. The aim of this narrative revision of the current literature is to demonstrate that (i) the orodispersible film of sildenafil is safe from a CV perspective; (ii) it is a discreet formulation that respects the need for privacy; and (iii) it is virtually the unique PDE5i formulation too expensive to produce outside the correct channels, making it impossible to be counterfeit.https://doi.org/10.1186/s12610-024-00245-yCardiovascular diseaseErectile disfunctionOral FilmPDE5iSildenafil |
| spellingShingle | Andrea Sansone Eugenia Guida Susanna Dolci Valeria Frangione Amanda Asso Gilberto Bellia Emmanuele A. Jannini Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status Basic and Clinical Andrology Cardiovascular disease Erectile disfunction Oral Film PDE5i Sildenafil |
| title | Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status |
| title_full | Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status |
| title_fullStr | Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status |
| title_full_unstemmed | Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status |
| title_short | Future perspectives for PDE5 inhibitors bridging the gap between cardiovascular health and psychological status |
| title_sort | future perspectives for pde5 inhibitors bridging the gap between cardiovascular health and psychological status |
| topic | Cardiovascular disease Erectile disfunction Oral Film PDE5i Sildenafil |
| url | https://doi.org/10.1186/s12610-024-00245-y |
| work_keys_str_mv | AT andreasansone futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus AT eugeniaguida futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus AT susannadolci futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus AT valeriafrangione futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus AT amandaasso futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus AT gilbertobellia futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus AT emmanueleajannini futureperspectivesforpde5inhibitorsbridgingthegapbetweencardiovascularhealthandpsychologicalstatus |